Peter Sallstig is the Global Head of Santen’s Product Development Division and the Chief Medical Officer (CMO) since April 2022. Guided by a passion for bringing innovation to ophthalmology, Peter is working to actively expand the global presence of Santen's development divisions and products in the field of ophthalmology.

Prior to being appointed CMO, Peter was Senior Vice President of the Development Department from 2018 to 2020, after which he was promoted to Corporate Officer of the Development Division in April 2020. He joined Santen in November 2018.

Previously, Peter was Vice-President of Clinical Development at Insmed Inc., a New Jersey-based biotechnology company focused on the treatment of rare pulmonology diseases, where he supported approval of the company’s first product to market, ARYKACE. Before that, Peter spent some over 12 years with Novartis, working on several blockbuster products in the field of rheumatology, cardiovascular and immunology and then with Alcon, holding several leadership positions, eventually rising to Global Head of Clinical Development of Alcon’s Pharmaceutical Franchise. At Alcon he also lead the design and development of the company’s first ever anti-vegf treatment, Brolicizumab.

Peter’s current focus is to transform Santen’s R&D, particularly its Product Development Division, to a best-in-class organization known for its capability to rapidly develop products while maintaining high quality, supported by top-level talent, to deliver true innovation for patients. As a keen advocate of innovation and associated digitalization, Peter aims to advance Santen’s concept of and approach to product development. Having worked across several therapeutic areas in his career, he is enthusiastically applying insights from these fields toward ophthalmology.

Peter holds a M.D. (Degree in medicine) degree from Semmelweis University, Hungary and an MBA from The Open University, UK.